| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 22 | 2025 | 499 | 4.300 |
Why?
|
| Immunogenicity, Vaccine | 21 | 2026 | 122 | 3.700 |
Why?
|
| Influenza, Human | 21 | 2025 | 702 | 3.640 |
Why?
|
| Antibodies, Viral | 38 | 2026 | 1166 | 3.290 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 8 | 2025 | 29 | 2.990 |
Why?
|
| Antibodies, Neutralizing | 25 | 2026 | 515 | 2.290 |
Why?
|
| Immunization, Secondary | 13 | 2026 | 119 | 2.180 |
Why?
|
| Vaccines | 7 | 2025 | 384 | 1.900 |
Why?
|
| Adjuvants, Immunologic | 14 | 2025 | 392 | 1.520 |
Why?
|
| Vaccines, Inactivated | 12 | 2025 | 149 | 1.310 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 2 | 2020 | 11 | 1.250 |
Why?
|
| HIV Infections | 10 | 2025 | 2025 | 1.210 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 5 | 2021 | 59 | 1.150 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 3 | 2025 | 62 | 1.060 |
Why?
|
| Respiratory Tract Infections | 3 | 2026 | 290 | 1.040 |
Why?
|
| Polysorbates | 8 | 2025 | 28 | 0.980 |
Why?
|
| Hemagglutination Inhibition Tests | 15 | 2025 | 112 | 0.940 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2013 | 422 | 0.930 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 13 | 0.910 |
Why?
|
| Adult | 64 | 2026 | 31533 | 0.890 |
Why?
|
| Histoplasmosis | 1 | 2025 | 55 | 0.880 |
Why?
|
| Neuraminidase | 1 | 2025 | 40 | 0.880 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2025 | 72 | 0.880 |
Why?
|
| Humans | 111 | 2026 | 130912 | 0.840 |
Why?
|
| Zika Virus Infection | 5 | 2024 | 178 | 0.820 |
Why?
|
| Vaccination | 17 | 2026 | 1036 | 0.810 |
Why?
|
| Tuberculosis | 5 | 2014 | 552 | 0.810 |
Why?
|
| Squalene | 7 | 2025 | 25 | 0.760 |
Why?
|
| Bacteremia | 2 | 2019 | 423 | 0.750 |
Why?
|
| Middle Aged | 49 | 2026 | 28730 | 0.740 |
Why?
|
| Pandemics | 5 | 2025 | 1157 | 0.740 |
Why?
|
| Zika Virus | 5 | 2024 | 155 | 0.700 |
Why?
|
| Microcephaly | 2 | 2024 | 352 | 0.690 |
Why?
|
| Young Adult | 29 | 2026 | 10037 | 0.680 |
Why?
|
| Male | 64 | 2026 | 64819 | 0.660 |
Why?
|
| Influenza in Birds | 1 | 2020 | 26 | 0.640 |
Why?
|
| Clostridium septicum | 1 | 2019 | 2 | 0.620 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 3 | 0.610 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 199 | 0.600 |
Why?
|
| Viral Vaccines | 4 | 2026 | 316 | 0.590 |
Why?
|
| Antitubercular Agents | 4 | 2013 | 264 | 0.590 |
Why?
|
| Population Surveillance | 5 | 2013 | 397 | 0.580 |
Why?
|
| Female | 63 | 2026 | 70740 | 0.580 |
Why?
|
| Viral Load | 3 | 2024 | 405 | 0.570 |
Why?
|
| Encephalitis | 1 | 2019 | 119 | 0.570 |
Why?
|
| Hemagglutinins | 2 | 2021 | 25 | 0.550 |
Why?
|
| Acanthamoeba | 1 | 2017 | 9 | 0.540 |
Why?
|
| Amebiasis | 1 | 2017 | 11 | 0.540 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 41 | 0.520 |
Why?
|
| Immunization Schedule | 7 | 2025 | 111 | 0.520 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2026 | 218 | 0.520 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 455 | 0.500 |
Why?
|
| Adolescent | 34 | 2026 | 20812 | 0.500 |
Why?
|
| Double-Blind Method | 17 | 2026 | 1632 | 0.490 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 262 | 0.490 |
Why?
|
| Anthrax Vaccines | 5 | 2016 | 26 | 0.480 |
Why?
|
| Clostridium Infections | 1 | 2019 | 248 | 0.480 |
Why?
|
| Smallpox Vaccine | 3 | 2025 | 38 | 0.470 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 391 | 0.470 |
Why?
|
| RNA, Viral | 3 | 2024 | 513 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2025 | 1248 | 0.440 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 348 | 0.440 |
Why?
|
| Francisella tularensis | 2 | 2017 | 16 | 0.440 |
Why?
|
| Seizures | 1 | 2019 | 875 | 0.430 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 104 | 0.430 |
Why?
|
| Guatemala | 6 | 2024 | 64 | 0.430 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 188 | 0.410 |
Why?
|
| Disease Outbreaks | 2 | 2008 | 313 | 0.410 |
Why?
|
| Aged | 23 | 2026 | 21134 | 0.380 |
Why?
|
| Adenosine Monophosphate | 2 | 2024 | 48 | 0.380 |
Why?
|
| Clinical Trials as Topic | 6 | 2025 | 1134 | 0.380 |
Why?
|
| Research Design | 3 | 2026 | 722 | 0.380 |
Why?
|
| Antigens, Viral | 2 | 2024 | 396 | 0.370 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2005 | 236 | 0.370 |
Why?
|
| Alanine | 2 | 2024 | 162 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 991 | 0.370 |
Why?
|
| Injections, Intradermal | 5 | 2025 | 29 | 0.360 |
Why?
|
| Dengue | 2 | 2024 | 123 | 0.360 |
Why?
|
| Urban Population | 1 | 2013 | 281 | 0.350 |
Why?
|
| Antibodies, Bacterial | 7 | 2017 | 425 | 0.350 |
Why?
|
| Aza Compounds | 1 | 2011 | 13 | 0.350 |
Why?
|
| Immunoglobulin G | 10 | 2025 | 809 | 0.340 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2026 | 76 | 0.330 |
Why?
|
| Malaria Vaccines | 1 | 2010 | 25 | 0.330 |
Why?
|
| Quinolines | 1 | 2011 | 118 | 0.320 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 80 | 0.320 |
Why?
|
| Malaria, Falciparum | 1 | 2010 | 70 | 0.320 |
Why?
|
| Injections, Intramuscular | 10 | 2025 | 186 | 0.310 |
Why?
|
| RNA, Messenger | 4 | 2023 | 2575 | 0.310 |
Why?
|
| Orthomyxoviridae | 2 | 2011 | 51 | 0.300 |
Why?
|
| Vaccines, Synthetic | 7 | 2026 | 320 | 0.300 |
Why?
|
| Case-Control Studies | 6 | 2025 | 3432 | 0.300 |
Why?
|
| Protozoan Proteins | 1 | 2010 | 135 | 0.300 |
Why?
|
| Healthy Volunteers | 6 | 2026 | 155 | 0.290 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1383 | 0.290 |
Why?
|
| Anthrax | 3 | 2014 | 30 | 0.290 |
Why?
|
| Child Development | 2 | 2021 | 271 | 0.280 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12858 | 0.280 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.270 |
Why?
|
| Brain | 1 | 2019 | 3161 | 0.270 |
Why?
|
| Antiviral Agents | 2 | 2024 | 811 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 844 | 0.250 |
Why?
|
| Organophosphonates | 1 | 2006 | 21 | 0.240 |
Why?
|
| Injections, Subcutaneous | 6 | 2025 | 132 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 33 | 0.240 |
Why?
|
| Chikungunya virus | 1 | 2026 | 28 | 0.240 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2025 | 10 | 0.240 |
Why?
|
| United States | 10 | 2025 | 11716 | 0.240 |
Why?
|
| Chikungunya Fever | 1 | 2026 | 32 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 794 | 0.230 |
Why?
|
| Immunity, Mucosal | 1 | 2025 | 90 | 0.230 |
Why?
|
| Texas | 8 | 2013 | 3604 | 0.230 |
Why?
|
| Placebos | 5 | 2016 | 227 | 0.230 |
Why?
|
| Histoplasma | 1 | 2025 | 37 | 0.230 |
Why?
|
| Administration, Mucosal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Adenine | 1 | 2006 | 124 | 0.230 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 222 | 0.220 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2005 | 82 | 0.220 |
Why?
|
| Infant | 9 | 2024 | 13210 | 0.220 |
Why?
|
| Patient Acuity | 2 | 2021 | 67 | 0.220 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 4 | 0.210 |
Why?
|
| Single-Blind Method | 2 | 2021 | 240 | 0.210 |
Why?
|
| Creatinine | 1 | 2006 | 402 | 0.210 |
Why?
|
| Azetidines | 2 | 2022 | 64 | 0.210 |
Why?
|
| Area Under Curve | 1 | 2024 | 317 | 0.210 |
Why?
|
| Dengue Virus | 2 | 2024 | 134 | 0.210 |
Why?
|
| Purines | 2 | 2022 | 115 | 0.210 |
Why?
|
| Nasopharynx | 1 | 2024 | 86 | 0.210 |
Why?
|
| Schistosomiasis mansoni | 1 | 2023 | 24 | 0.200 |
Why?
|
| Water Microbiology | 1 | 2002 | 28 | 0.190 |
Why?
|
| Water Supply | 1 | 2002 | 26 | 0.190 |
Why?
|
| Incidence | 4 | 2021 | 3326 | 0.190 |
Why?
|
| Aedes | 1 | 2023 | 101 | 0.190 |
Why?
|
| Mycobacterium | 1 | 2002 | 30 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2025 | 298 | 0.190 |
Why?
|
| Vomiting | 1 | 2023 | 104 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 45 | 0.190 |
Why?
|
| Mycobacterium Infections | 1 | 2002 | 34 | 0.190 |
Why?
|
| Vancomycin | 1 | 2024 | 225 | 0.190 |
Why?
|
| Cough | 1 | 2023 | 99 | 0.190 |
Why?
|
| Vaccinia virus | 2 | 2025 | 50 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2022 | 290 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 5256 | 0.180 |
Why?
|
| Growth Disorders | 1 | 2023 | 185 | 0.180 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 61 | 0.180 |
Why?
|
| Pyrazoles | 2 | 2022 | 352 | 0.170 |
Why?
|
| Vaccines, Attenuated | 3 | 2017 | 173 | 0.170 |
Why?
|
| Diarrhea | 1 | 2023 | 311 | 0.170 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 45 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 6862 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 790 | 0.170 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 482 | 0.170 |
Why?
|
| DNA, Bacterial | 3 | 2011 | 492 | 0.160 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 81 | 0.160 |
Why?
|
| Critical Illness | 1 | 2024 | 612 | 0.160 |
Why?
|
| Occupational Health | 1 | 2020 | 46 | 0.160 |
Why?
|
| Mycobacterium avium Complex | 2 | 2021 | 20 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 6443 | 0.160 |
Why?
|
| Birds | 1 | 2020 | 86 | 0.160 |
Why?
|
| Motor Skills | 1 | 2020 | 75 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 172 | 0.160 |
Why?
|
| Lipid A | 1 | 2019 | 23 | 0.160 |
Why?
|
| Language Tests | 1 | 2019 | 25 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2025 | 555 | 0.150 |
Why?
|
| Schistosomiasis | 1 | 2019 | 52 | 0.150 |
Why?
|
| Cytokines | 3 | 2020 | 1340 | 0.150 |
Why?
|
| Cross Infection | 1 | 2002 | 338 | 0.150 |
Why?
|
| Glucosides | 1 | 2019 | 53 | 0.150 |
Why?
|
| Antibodies, Helminth | 1 | 2019 | 131 | 0.150 |
Why?
|
| Body Fluids | 1 | 2019 | 46 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 677 | 0.140 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 608 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 92 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 1235 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 138 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 177 | 0.140 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 500 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 1006 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 403 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2558 | 0.130 |
Why?
|
| Influenza B virus | 2 | 2023 | 102 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 210 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2024 | 14944 | 0.130 |
Why?
|
| Learning | 1 | 2020 | 369 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 117 | 0.120 |
Why?
|
| Child | 7 | 2024 | 26096 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 176 | 0.120 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Caregivers | 1 | 2021 | 581 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 279 | 0.120 |
Why?
|
| Cholecystitis | 1 | 2015 | 20 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2022 | 5095 | 0.110 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 24 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 389 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 365 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 548 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 379 | 0.110 |
Why?
|
| Biomarkers | 1 | 2024 | 3365 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 357 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2015 | 132 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 260 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 3396 | 0.100 |
Why?
|
| Molecular Epidemiology | 2 | 2005 | 146 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 185 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 34275 | 0.100 |
Why?
|
| Psychometrics | 3 | 2021 | 666 | 0.090 |
Why?
|
| Bacillus anthracis | 2 | 2009 | 39 | 0.090 |
Why?
|
| Risk Factors | 4 | 2013 | 10900 | 0.090 |
Why?
|
| China | 2 | 2024 | 286 | 0.090 |
Why?
|
| Erythema Infectiosum | 1 | 2011 | 5 | 0.090 |
Why?
|
| Prevalence | 2 | 2011 | 2679 | 0.090 |
Why?
|
| Mortality | 1 | 2013 | 261 | 0.090 |
Why?
|
| Schistosoma mansoni | 2 | 2023 | 24 | 0.090 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 26 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 339 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 228 | 0.090 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 32 | 0.090 |
Why?
|
| Ofloxacin | 1 | 2011 | 30 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2010 | 16 | 0.080 |
Why?
|
| alpha-Tocopherol | 2 | 2024 | 36 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2011 | 94 | 0.080 |
Why?
|
| Human Experimentation | 1 | 2010 | 32 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 74 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2025 | 267 | 0.080 |
Why?
|
| Rural Population | 2 | 2024 | 256 | 0.080 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 99 | 0.080 |
Why?
|
| Phosphates | 1 | 2010 | 110 | 0.080 |
Why?
|
| Plasmodium falciparum | 1 | 2010 | 96 | 0.080 |
Why?
|
| Pregnancy | 4 | 2024 | 7551 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2024 | 277 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 149 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 45 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17483 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2950 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 213 | 0.070 |
Why?
|
| Logistic Models | 2 | 2005 | 1822 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 741 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 476 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3833 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2122 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 371 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 298 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2009 | 542 | 0.060 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2006 | 10 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3610 | 0.060 |
Why?
|
| Measles virus | 1 | 2026 | 16 | 0.060 |
Why?
|
| Tenofovir | 1 | 2006 | 25 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1311 | 0.060 |
Why?
|
| Neutralization Tests | 2 | 2017 | 226 | 0.060 |
Why?
|
| Research | 1 | 2008 | 266 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 990 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2011 | 931 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 1741 | 0.060 |
Why?
|
| Immunity, Humoral | 1 | 2025 | 76 | 0.060 |
Why?
|
| Cities | 1 | 2004 | 50 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 75 | 0.050 |
Why?
|
| Urban Health | 1 | 2004 | 85 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carrier State | 1 | 2004 | 80 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 196 | 0.050 |
Why?
|
| Benzoin | 1 | 2023 | 6 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 310 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.050 |
Why?
|
| Aluminum Hydroxide | 1 | 2023 | 40 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2023 | 132 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 140 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 243 | 0.050 |
Why?
|
| Reference Values | 1 | 2004 | 689 | 0.050 |
Why?
|
| Protozoan Vaccines | 1 | 2023 | 99 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 283 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 313 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1395 | 0.050 |
Why?
|
| Bacterial Toxins | 2 | 2016 | 171 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 167 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 101 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6275 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.040 |
Why?
|
| Seasons | 1 | 2023 | 331 | 0.040 |
Why?
|
| Antigens, Bacterial | 2 | 2016 | 319 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 258 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 896 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 28 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1490 | 0.040 |
Why?
|
| Ethambutol | 1 | 2000 | 6 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 17 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 92 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8541 | 0.040 |
Why?
|
| Recurrence | 1 | 2004 | 1473 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 330 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 124 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 428 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2000 | 419 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 29 | 0.040 |
Why?
|
| Rural Health | 1 | 2019 | 42 | 0.040 |
Why?
|
| Child Language | 1 | 2019 | 28 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 51 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 555 | 0.040 |
Why?
|
| Semen | 1 | 2019 | 85 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2019 | 187 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 136 | 0.030 |
Why?
|
| Mothers | 1 | 2021 | 369 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Seroconversion | 1 | 2017 | 15 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 67 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 503 | 0.030 |
Why?
|
| Equivalence Trials as Topic | 1 | 2017 | 22 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 2017 | 42 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1164 | 0.030 |
Why?
|
| Vagina | 1 | 2019 | 210 | 0.030 |
Why?
|
| Baculoviridae | 1 | 2017 | 41 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 3799 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2017 | 106 | 0.030 |
Why?
|
| Emulsions | 1 | 2017 | 69 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 317 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1625 | 0.030 |
Why?
|
| Hemagglutination, Viral | 1 | 2015 | 9 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1069 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 51 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 307 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3675 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 224 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 1767 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 169 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 266 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1925 | 0.020 |
Why?
|
| Pharynx | 1 | 2011 | 64 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4007 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 530 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2011 | 150 | 0.020 |
Why?
|
| Nose | 1 | 2011 | 112 | 0.020 |
Why?
|
| New York | 1 | 2009 | 69 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 82 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 152 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2866 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 632 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 215 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 18408 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2002 | 6 | 0.010 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentosyltransferases | 1 | 2000 | 18 | 0.010 |
Why?
|
| Operon | 1 | 2000 | 49 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2002 | 409 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 801 | 0.010 |
Why?
|